home / stock / myok / myok quote
Last: | $224.91 |
---|---|
Change Percent: | 0.05% |
Open: | $224.82 |
Close: | $224.91 |
High: | $225 |
Low: | $224.52 |
Volume: | 2,741,364 |
Last Trade Date Time: | 11/16/2020 04:56:40 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$224.91 | $224.82 | $224.91 | $225 | $224.52 | 2,741,364 | 11-16-2020 |
$224.8 | $224.7 | $224.8 | $224.85 | $224.7 | 1,244,191 | 11-13-2020 |
$224.74 | $224.43 | $224.74 | $224.84 | $224.43 | 1,350,528 | 11-12-2020 |
$224.41 | $224.48 | $224.41 | $224.53 | $224.23 | 2,022,640 | 11-11-2020 |
$224.55 | $224.45 | $224.55 | $224.57 | $224.35 | 939,058 | 11-10-2020 |
$224.41 | $224.58 | $224.41 | $224.58 | $224.165 | 1,452,938 | 11-09-2020 |
$224.41 | $224.49 | $224.41 | $224.57 | $224.4 | 1,202,776 | 11-06-2020 |
$224.4 | $224.45 | $224.4 | $224.63 | $224.4 | 646,503 | 11-05-2020 |
$224.56 | $224.32 | $224.56 | $224.61 | $224.3 | 1,532,659 | 11-04-2020 |
$223.49 | $223.35 | $223.49 | $223.595 | $223.15 | 1,108,872 | 11-03-2020 |
$223.28 | $223.36 | $223.28 | $223.425 | $223.09 | 1,074,203 | 11-02-2020 |
$223.53 | $223.04 | $223.53 | $223.55 | $222.985 | 686,518 | 10-30-2020 |
$223.32 | $223 | $223.32 | $223.49 | $222.8 | 608,035 | 10-29-2020 |
$222.805 | $222.81 | $222.805 | $223.135 | $222.685 | 814,745 | 10-28-2020 |
$222.91 | $223.25 | $222.91 | $223.25 | $222.81 | 426,506 | 10-27-2020 |
$223 | $222.54 | $223 | $223 | $222.5 | 437,100 | 10-26-2020 |
$222.97 | $222.25 | $222.97 | $222.98 | $222.25 | 540,207 | 10-23-2020 |
$222.14 | $222.66 | $222.14 | $222.845 | $222.1 | 1,253,430 | 10-22-2020 |
$222.4 | $222.7 | $222.4 | $222.8394 | $222.4 | 1,002,425 | 10-21-2020 |
$222.45 | $222 | $222.45 | $222.68 | $221.9 | 649,222 | 10-20-2020 |
News, Short Squeeze, Breakout and More Instantly...
EXPLORER -HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten T reatment Resulted in Favorable Effect on Cardiac Structure -- Significantly Reduced Hypertrophy in Patien...
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from MAVERICK-HCM Accelerometry Data Correlated with ...
BRISBANE, Calif. and WASHINGTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovas...